



140

1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gennady MERKULOV et al. Art Unit: 1642

Serial No.: 09/820,003

Examiner: S. Rawlings

Filed: March 29, 2001

Atty. Docket: CL001196

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC  
ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE  
PROTEINS, AND USES THEREOF

TECH CENTER 1600/2900

NOV 12 2003

RECEIVED


**Statement Regarding Duty to Disclose Information Material To Patentability Under  
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.



No fee is due for this IDS Submission. However, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,  
CELERA GENOMICS

Date: October 20, 2003

Celera Genomics Corporation  
45 West Gude Drive, C2-4#21  
Rockville, MD 20850  
Tel: 240-453-3812  
Fax: 240-453-3084

By:   
Justin D. Karjala, Reg No. 43,704

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

<b>Application Number</b>	09/820,003
<b>Filing Dat</b>	March 29, 2001
<b>First Nam d Inventor</b>	Gennady MERKULOV et al.
<b>Art Unit</b>	1642
<b>Examiner Name</b>	S. Rawlings
<b>Attorney Docket Number</b>	CI.001196

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Foreign Patent Document						Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Country Code <sup>3</sup>	Number <sup>1</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		WO	00 58356 A1	10-5-2000	Human Genome Sciences		

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

